Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02

1. Rivera, F.
2. Massutí, B.
3. Salcedo, M.
4. Sastre, J.
5. Martínez Galán, J.
6. Valladares-Ayerbes, M.
7. Serrano, R.
8. De Paredes, Ma.L.G
9. Manzano, J.L.
10. Galán, M.
11. Alsina, M.
12. Yuste Izquierdo, A.L.
13. López, C.
14. Díaz-Rubio, E.
15. Conde, V.
16. Reboredo, M.
17. Cano, Ma.T.
18. Pachón, V.
19. Aranda, E.